

DSM Pharmaceutical Products
45 Waterview Blvd
Parsippany, NJ 07054-1298

October 10, 2006

DSM Biologics and Argenes Inc. Sign a Biopharmaceutical Manufacturing Agreement

Parsippany, October 10, 2006

DSM Biologics (headquartered in Parsippany, NJ) and Argenes, Inc. (headquartered in Tokyo, Japan) have signed a Biopharmaceutical Manufacturing Agreement. Under the terms of the Agreement DSM Biologics will provide Argenes with (a) full process development services, (b) full analytical development services and (c) manufacturing batches for Argenes' Anti-Fas IgM monoclonal antibody. The services will be provided out of DSM Biologics' FDA-approved manufacturing facility in Groningen, The Netherlands.

Argenes' Anti-FAS IgM monoclonal antibody is being developed as an anti-rheumatic agent.

Both parties are very pleased with the results of the collaboration to date. "The agreement is a further reinforcement of the strong and mutually beneficial relationship between Argenes and DSM Biologics. We gladly entrust DSM Biologics with the execution of this Agreement that is crucial for the success of our Anti-Fas IgM monoclonal antibody" says Kamishohara, President & CEO of Argenes, Inc.

"DSM Biologics is very pleased to be involved in this exciting project. The agreement is a clear recognition of the value that DSM Biologics has brought, and will continue to bring to Argenes, an important client for DSM Biologics" says Terry Novak, Chief Marketing Officer of DSM Biologics.

About DSM Biologics

DSM Biologics, a business unit of DSM Pharmaceutical Products, is a leading provider of manufacturing technology & services to the biopharmaceutical industry. In addition to offering world-class biopharmaceutical manufacturing services, DSM Biologics has co-exclusive rights, along with Dutch biotech company Crucell N.V., to license the high-producing PER.C6® human cell line as a production platform for recombinant proteins and monoclonal antibodies. DSM Biologics' FDA-approved facility in Groningen, the Netherlands was established in 1986, and has a strong track record in using a broad range of cell lines (PER.C6®, CHO, hybridoma, etc.) in biopharmaceutical manufacturing, and has a wide-range of experience using multiple manufacturing (batch, fed-batch and continuous perfusion) and purification techniques. The combination of the PER.C6® human cell line and DSM's manufacturing services provides companies with a turn-key biologic manufacturing solution reducing cost, risk and time to market. DSM Biologics is being represented in Japan by Asahi Glass & Co., Ltd. For more information, please visit www.dsmbiologics.com.

About Argenes

Argenes is a bio-venture related to St. Marianna University School of Medicine, and it specializes in the development of new therapeutics for the treatment of intractable diseases such as rheumatoid arthritis, fibromyalgia and other musculoskeletal disease. Argenes contributes to improve a healthy and rich lifestyle through the development and commercialization of new pharmaceuticals based on medical knowledge and intellectual property of St. Marianna University School of Medicine, with its development ability, and by forming strategic alliances with pharmaceutical companies. Since its establishment in 2004 it has received support from venture capitals and pharmaceutical companies, has maximized its advantages as a venture by making fast and effective operation and business decision, and continues to develop novel therapeutics such as the anti-Fas monoclonal antibody ARG098 for a rheumatoid arthritis treatment, and ARG171 for a fibromyalgia treatment.

Forward-looking statements

Statements included in this press release which are not historical in nature are intended to be, and are hereby identified as, “forward-looking statements” for purposes of the safe harbor provided by Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words including “anticipates”, “believes”, “intends”, “estimates”, “expects” and similar expressions. The company cautions readers that forward-looking statements, including without limitation those relating to the company’s future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Factors that may affect future operations and business prospects include, but are not limited to, clinical and scientific results and developments concerning corporate collaborations and the company’s proprietary rights.

For more information:

DSM Pharmaceutical Products

Terry Novak
Chief Marketing Officer
973-257-8471
Terry.Novak@dsm.com

DSM Biologics

Brad Carlson
Vice President, Marketing, Sales & NBD
Tel. +1 (585) 624-3844
Brad.Carlson@dsm.com

DSM Biologics

Marcel Lubben
Manager, New Business Development
Europe & Asia
+31 46 47 73343
Marcel-m.lubben@dsm.com

Argenes, Inc.

Mr. Naoki Kobayashi
Director, Corporate Planning & CFO
info@argenes.co.jp